SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020 - 2019 - 2018 - 2017

December 2017 Autoimmune News

The Doctor–Delayed Diagnosis. While awaiting a correct diagnosis, patients frequently experience worsening symptoms, a decline in overall health and even death. IG Living, 11/02/2017. (Also see Difficult Diagnosis)

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis (RA) patients to tocilizumab. RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. Seminars in Arthritis and Rheumatism, 11/03/2017. (Also see Treatments for Rheumatoid Arthritis and Interleukins)

Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis (PsA): a population–based cohort study. In a primary care–based incidence cohort of patients with PsA, there were substantial risks of developing uveitis and/or Crohn's disease, but not ulcerative colitis, when compared with the general population and psoriasis controls. PubMed, Ann Rheum Dis, 11/01/2017. (Also see Psoriasis and Psoriatic Arthritis and Inflammatory Bowel Disease)

Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome (pSS) and is associated with systemic disease activity. Severe intestinal dysbiosis is a prevalent finding in pSS and is associated both with clinical and laboratory markers of systemic disease activity as well as gastrointestinal inflammation. PubMed, Arthritis Res Ther, 2017 Oct 24;19(1):237. (Also see Symptoms and Complications of Sjogren's Syndrome)

Association between leptin and IL-6 concentrations with cardiovascular risk (CVR) in patients with rheumatoid arthritis. There is a positive association between CVR and serum leptin concentrations and it is also significantly associated with traditional and non–traditional risk factors. PubMed, Clin Rheumatol, 11/03/2017. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Acute effect of a resistance exercise (RE) session on markers of cartilage breakdown and inflammation in women with rheumatoid arthritis (RA). Women with and without RA have similar changes in response to a RE session in levels of inflammation biomarkers, but not of cartilage breakdown. PubMed, Int J Rheum Dis, 11/03/2017. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Infections and the risk of psoriatic arthritis (PsA) among psoriasis patients: a systematic review. While the studies summarized did not all provide evidence supporting an association between infections and PsA certain trends emerged. PubMed, Rheumatol Int, 11/09/2017. (Also see Psoriasis and Psoriatic Arthritis)

Risk of incident liver disease in patients with psoriasis (PsO), psoriatic arthritis (PsA) and rheumatoid arthritis (RA): a population–based study. More so than RA, PsO and PsA are associated with liver disease, particularly non-alcoholic fatty liver disease and cirrhosis, and this was true even among patients without systemic therapy exposure. PubMed, J Invest Dermatol, 10/27/2017. (Also see Psoriasis and Psoriatic Arthritis and Symptoms and Complications of Rheumatoid Arthritis)

Human microbiome, infections, and rheumatic disease. It is now clear that there is direct and indirect cross talk between the microbiome and host immune responses. PubMed, Clin Rheumatol, 2017 Dec;36(12):2645-2653. (Also see Systemic Autoimmune Rheumatic Diseases)

Length of exposure to antiphospholipid antibodies (aPL), rather than age, is a risk factor for thrombosis: a retrospective single–centre observational study. Unlike age, lack of thromboprophylaxis, prolonged aPL exposure and lupus anticoagulant may increase the risk of thrombosis in aPL carriers. PubMed, Rheumatol Int, 11/10/2017. (Also see Antiphospholipid Syndrome)

Go to Autoimmune News: November 2017
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!